CYP3A4 and colorectal carcinoma: Although this treatment strategy could be an option for BRAF-mutated PM-CRC, caution should be taken as CYP3A4, discussed above, is also known to metabolize several BRAF and EGFR inhibitors, such as Vemurafenib [46], Encorafenib [47] and Erlotinib [48], and might reduce the efficacy of the drugs.